Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Erelzi | Etanercept | Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cerdelga | Eliglustat | Gaucher disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dysport Therapeutic | abobotulinumtoxinA | Cervical dystonia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hemangiol | Propranolol oral solution | Infantile hemangioma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ravicti | glycerol phenylbutyrate | Urea cycle disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Actikerall | Fluorouracil and Salicylic Acid | Hyperkeratotic actinic keratosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zelboraf | Vemurafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin | Bevacizumab | Cervical Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 28, 2024